The strongest molecular associations with response were noted in patients with NPM1, IDH1 and IDH2 mutations, with CR/CRi rates exceeding 80%, in particular in NPM1 and IDH2 mutated patients [91] Similar results were reported in larger clinical studies of VEN + HMA in newly diagnosed and r/r AML patients, including VIALE-A, the large phase III trial [71], in which IDH-mutated patients consistently reached high response rates leading to long lasting remissions and improved OS (Table 3) [86,87,91,92,93,94]. Here, IDH2 is linked to acute myeloid leukemia.